Additionally, the present study demonstrated that reducing myocardial fibrosis and cardiomyocyte hypertrophy by inhibition of TGF-β and ERK/MAPK signaling pathways may be the key pharmacological mechanism of STDP in ameliorating CHF. Here, TGFB1 is linked to Myocardial fibrosis.